

**This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.**

**Authors:** Ammar Ali Ahmed, Abdulkareem M. Jewad

**Article type:** Original Article

**Received:** 8 February 2025

**Accepted:** 5 June 2025

**Published online:** 15 August 2025

**eISSN:** 2544-1361

**Eur J Clin Exp Med**

**doi:** 10.15584/ejcem.2025.4.2

**This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our authors we are providing this early version of the manuscript. The manuscript will undergo copyediting and typesetting. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.**

# Evaluation of adrenomedullin, growth differentiation factor-15, and atrial natriuretic peptide in patients with rheumatoid arthritis

Ammar Ali Ahmed, Abdulkareem M. Jewad

College of Health and Medical Techniques/Al-Basrah, Southern Technical University, Ministry of Higher Education and Scientific Research, Iraq

**Corresponding author:** Ammar Ali Ahmed, e-mail: ammar.a.ahmed@fgs.stu.edu.iq

## ORCID

AAA: <https://orcid.org/0009-0002-1069-7748>

AMJ: <https://orcid.org/0000-0003-0608-4279>

## ABSTRACT

**Introduction and aim.** Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation and systemic complications, including cardiovascular involvement. This study evaluated the diagnostic utility of angiotensinogen (AGT), serum amyloid A-4 protein (SAA4) and C-reactive protein (CRP) in RA, along with new cardiac biomarkers adrenomedullin (ADM), growth differentiation factor-15 (GDF-15), and atrial natriuretic peptide (ANP), to assess cardiac complications.

**Material and methods.** This case-control study included 61 RA patients (divided into newly diagnosed, sDMARD-treated, and sDMARD/bDMARD-treated groups) and 27 healthy controls. Serum levels of AGT, SAA4, CRP, ADM, GDF-15, and ANP were measured using ELISA. Statistical analyses were performed using SPSS software.

**Results.** RA patients exhibited significantly elevated levels of AGT ( $40.841 \pm 17.285$   $\mu\text{g/mL}$ ), SAA4 ( $48.128 \pm 17.065$   $\text{ng/mL}$ ), CRP ( $13.097 \pm 18.702$   $\text{mg/L}$ ), ADM ( $96.295 \pm 19.424$   $\text{pg/mL}$ ), GDF-15 ( $1247.049 \pm 854.335$   $\text{pg/mL}$ ), and ANP ( $334.016 \pm 40.874$   $\text{pg/mL}$ ) levels compared to controls ( $p \leq 0.001$ ). No significant differences were observed between the treatment groups for AGT, SAA4, or CRP levels. Cardiac biomarkers (ADM, GDF-15, and ANP) remained elevated in all RA groups, with strong inter-parameter correlations (Spearman  $r > 0.6$ ).

**Conclusion.** AGT, SAA4, and CRP demonstrate robust diagnostic value for RA. Persistent elevation of ADM, GDF-15, and ANP in all patient groups confirms significant cardiac involvement in RA.

**Keywords.** adrenomedullin, angiotensinogen, growth differentiation factor-15, serum amyloid A-4 protein, rheumatoid arthritis

## Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily causes symmetric joint inflammation, pain, and swelling. It typically begins in small joints and progresses to larger ones. RA can also affect multiple systems, including the integumentary, ocular, cardiac, renal, and pulmonary.<sup>1,2</sup> Joint involvement leads to erosion of the bone and cartilage, potentially weakening surrounding muscles and ligaments. Its development involves both genetic and environmental factors.<sup>3,4</sup> Recent studies have focused on innovative biochemical markers to diagnose RA, including angiotensinogen (AGT) and serum amyloid A-4 protein (SAA4).<sup>5</sup> AGT is predominantly synthesized in the liver.<sup>6</sup> The conversion of AGT to angiotensin I is catalyzed by the enzyme renin, which is generated by juxtaglomerular cells in the renal cortex. Several components of inflammatory reactions in various tissues are part of the renin-angiotensin system (RAS). The pathophysiology of RA is influenced by several components of this system, including enzymes and peptides.<sup>7</sup> Two opposing but balanced components, classical and protective, regulate blood pressure, body fluid, and electrolyte homeostasis in RAS. Pathological inflammatory disorders such as RA can alter this balance and change the plasma concentrations of its components.<sup>8</sup>

SAA4 is an essential acute phase protein in inflammatory rheumatic diseases (IRD). Recent studies have confirmed the role in IRD pathogenesis. Human SAA4 proteins include 104 amino acids and are conserved throughout the mammalian history.<sup>9</sup> Synthesis is performed in the liver and not just in the liver. SAA Insoluble fibrils are formed by solid aggregates, the "amyloid" of "secondary" amyloid disease. Buildups may impair biological activities and cause organ dysfunction. RA is commonly diagnosed by measuring CRP levels to indicate systemic inflammation.<sup>10</sup>

The atrium produces most of the ANP by processing its precursor into prohormones and conserving them in secretory granules within the atrial cardiomyocytes. Elimination separates them into NT-ProANP and ANP.<sup>11</sup> The release of ANP is initiated by distension of the atrial walls, serving two primary functions: promoting vasodilation and improving renal excretion of sodium and water.<sup>12</sup> There is a substantial association occurs between the mechanical and endocrine activities of the heart in individuals with cardiac disease, perhaps indicating the stage and severity of the condition.<sup>13</sup> Natriuretic peptides are essential for heart physiology and pathology. A thorough understanding of their control in both normal and pathological cardiac states may improve diagnostic precision and treatment strategies, particularly for heart failure (HF) and atrial fibrillation (AF), which are intimately interconnected in a cyclical way. The role of ANP in endocrine activity requires a comprehensive examination to clarify the effects of this peptide on mechanical function.<sup>14</sup> Elevated levels of ANP are often seen in individuals with HF and  $\beta$ -thalassemia major, making them significant indicators for the diagnosis and prognosis of this illness.<sup>15</sup>

A divergent member of the transforming growth factor- $\beta$  superfamily, growth differentiation factor-15 GDF-15, is alternatively referred to as a cytokine that inhibits macrophage (MIC)-1.<sup>16</sup> This superfamily includes several other proteins. When heart myocytes experience ischemia or increased stress on the

ventricular wall, their expression of GDF-15 is dramatically increased, in contrast to the usual, low expression of this factor in most tissues. The regulation of GDF-15, a stress-inducible cytokine, appears to be complicated and tissue specific, as it is controlled by many inflammatory or stress-related proteins such as IL-1  $\beta$ , TNF- $\alpha$ , interleukin-2, and MCSF-1.<sup>17</sup> The precise role of GDF-15 remains unclear; however, it appears to confer protection against cardiac injury through its anti-hypertrophic, anti-apoptotic, and anti-inflammatory properties, which are potentially mediated by its interaction with an unidentified receptor.<sup>18</sup> GDF-15 is an effective prognostic indicator of cardiovascular complications. Experimental murine ischemia/reperfusion injury models demonstrate a rapid increase in circulating and tissue GDF15 levels after cardiac injury, with elevations that persist for several day.<sup>19</sup> GDF-15 levels are also significantly elevated in patients with  $\beta$ -thalassemia major.<sup>20</sup>

Adrenomedullin (ADM), which was initially discovered in pheochromocytoma tissue in 1993, is currently one of the most significant current cardiac indicators.<sup>21</sup> The peptide consists of 52 amino acids. After translation, pro-adrenomedullin (proADM) is produced and converted into biologically active adrenomedullin (bio-ADM).<sup>22</sup> Various body organs, including the kidneys, lungs, endocrine system and cardiovascular system, produce pro-ADM and bio-ADM in response to volume overload, commonly observed in heart failure.<sup>23</sup> Elevated levels of bio-ADM levels in HF suggest a mechanism to mitigate volume overload by stabilizing the function of the endothelial barrier function.<sup>24</sup> There is a critical need for biomarkers that facilitate precise assessment of congestion, as accurately measuring congestion is notoriously challenging due to significant observer variability. Recent studies have demonstrated a significant correlation between elevated bio-ADM levels and systemic congestion as well as negative outcomes, independent of NT-proBNP. Bio-ADM is a useful biomarker for the diagnosis of HF and the assessment of clinical outcomes.<sup>25</sup>

## **Aim**

This study aimed to evaluate the diagnostic and monitoring efficacy of two novel rheumatoid biomarkers (AGT and SAA4) in patients with RA. Furthermore, we sought to assess cardiac complications associated with RA by quantifying circulating levels of cardiac biomarkers, including ADM, GDF-15, and atrial natriuretic peptide (ANP).

## **Material and methods**

A case-control study was conducted between November 2023 and June 2024 among RA patients who were subjected to different therapeutic regimens. Participants were recruited from rheumatology clinics at the Al-Basrah Teaching Hospital and Al-Mawanah Teaching Hospital in the Basra Governorate, Iraq. Group 1 (Newly diagnosed): n=10, no previous treatment with disease-modifying anti-rheumatic drugs (DMARD). Group 2 (sDMARD-treated): n=22, receiving conventional synthetic DMARD (csDMARD):

methotrexate and sulfasalazine) for 3 months. Group 3 (bDMARD-Treated): n=29, receiving biologic DMARDs (bDMARDs: anti-IL6 agents Tocilizumab or Sarilumab) in addition to csDMARDs. Control group: n=27, healthy volunteers of the same age and sex were included as controls. The study excluded all participants with preexisting chronic diseases, including cardiovascular disease (for example, hypertension, heart failure), diabetes, liver/kidney dysfunction or active infections, as well as individuals outside the 20–66 age range, to focus on patients with RA diagnosed according to the 2010 ACR/EULAR criteria with 6 months of disease duration, willingness to provide informed consent and no recent corticosteroid use (within 3 months). Disease activity in patients with RA was evaluated using DAS28-ESR. The control group consisted of healthy volunteers from the Basra Governorate, matched with RA patients by age and sex, with no history of autoimmune diseases, chronic inflammation, or recent infections. Samples from both groups were collected in a dedicated laboratory within the same geographic region to ensure consistency. The excluded criteria uniformly applied to both groups included barred pregnant individuals and those with acute or chronic comorbidities.

An agreement was signed to conduct this study before the start of the sample collection process. The study design allowed the evaluation of disease progression and treatment efficacy at different stages of RA management, while the inclusion of a control group allowed the exploration of possible biomarkers and clinical parameters that are specific to patients with RA.

A total of 61 RA patients participated in the study, and the sample size was derived from a combination of statistical and practical considerations. Patient availability, resources, time constraints, ethical considerations, and data from the pilot study contributed to the final sample size. Other factors that have limited patient availability include the prevalence of the disease at the study location. Due to time limitations, the number of patients recruited and followed fell within the specified time frame. In making this decision, ethical dimensions around minimizing the burden on participants while retaining scientific rigor were also important considerations. Data from a pilot study could have adjusted the sample size based on the expectation that 61 patients would be sufficiently motivated to discover clinically meaningful differences. As it is pragmatic in the context of real-life clinical research that involves many investigators, statistical power cannot always be achieved when faced with the practical limitations of the real healthcare environment.

### ***Ethical considerations***

The present study was fully approved by the Training and Human Development Unit of the Basrah Health Department, which is part of the Ministry of Health in Iraq. This proposal was authorized by the research committee (number 860/2023) on 23 December 2023, in accordance with the Declaration of Helsinki.

### Laboratory tests

A sterile gel tube was used to collect whole blood. As a result, the serum was separated for serological testing and ELISA. All kits used were manufactured by Fine Test Company, China. ANG, Cat: EH0550, SAA4, Cat.: EH1155, ANP, Cat. EH2639; GDF-15, Cat.: EH0150, ADM, Cat: EH0779, and C-Reactive Protein (CRP), REF: ACN 210, levels were measured using a human-adaptable ELISA kit from Shanghai Ideal Medical Technology Co., Ltd., and absorbance was measured at a wavelength of 450 nm using a BioTek (USA) 800TS microplate reader.

### Statistical analysis

For tabulation and analysis, SPSS spreadsheet version 26.0 was used. Excel was used to display important facts. For each cardiac and rheumatic parameter, the means and standard deviations were calculated for the control, pretreatment, sDMARDs and bDMARDs groups. The Kolmogorov test determined the normality of the variable, which is a prerequisite for parametric and nonparametric analyses. Tables 1 and 2 show how the Mann-Whitney U test was used to compare the control and patient groups. For each biomarker, the Kruskal-Wallis test and post hoc pairwise comparisons were used to compare the four groups (Tables 3 and 4). Spearman's rank correlation coefficient was used to assess the relationships between the biomarkers.

### Results

This study compared biochemical markers associated with RA in controls (n=27) and patients with RA (n=61). Demographic and clinical characteristics, including age, sex, and body mass index (BMI), were compared between cohorts. No significant differences were observed in age (patients: 46.57±9.65 years; controls: 43.55±8.06 years; p=0.315) or gender distribution (males: 36% vs 33%, females: 64% vs. 67%; p=0.3). However, RA patients exhibited higher BMI values compared to controls (28.6±2.1 kg/m<sup>2</sup> vs. 23.6±1.9 kg/m<sup>2</sup>; p=0.02). Different CRP, SAA4 and AGT values were observed. RA patients had significantly higher levels of all indicators than the control group (p <0.001) (Table 1).

**Table 1.** Evaluation of biomarker concentrations in control and patient cohorts\*

		Patients (n=61)	Control (n= 27)	p
Age		46.57±9.65	43.55±8.06	0.315 <sup>a</sup>
Gender	Male, n (%)	22 (36 %)	9 (33 %)	0.3 <sup>b</sup>
	Female, n (%)	39 (64 %)	18 (67 %)	
BMI (kg/m <sup>2</sup> )		28.6±2.1	23.6±1.9	0.02 <sup>a</sup>
SAA4 (ng/mL)		48.128±17.065	2.210±0.647	<0.0001 <sup>a</sup>
AGT (µg/mL)		40.841±17.285	3.573±1.413	<0.0001 <sup>a</sup>
CRP (mg/l)		13.097±18.702	0.756±0.109	<0.0001 <sup>a</sup>

\* <sup>a</sup> – Mann Whitney's test, <sup>b</sup> – Chi-square

Table 2 indicates substantial changes in all cardiac biomarkers between patients and controls. Patients showed significantly higher serum levels of ADM levels ( $96.295 \pm 19.424$  pg/mL) than those of the control group ( $4.191 \pm 0.543$  pg/mL) ( $p < 0.001$ ). The patient group had substantially higher levels of GDF15 levels ( $1247.049 \pm 854.335$  pg/mL) compared to the control group ( $41.089 \pm 14.884$  pg/mL) ( $p < 0.001$ ); the sick group exhibited considerably higher levels of ANP levels ( $334.016 \pm 40.874$  pg/mL) than the control group ( $58.200 \pm 19.592$  pg/mL) ( $p < 0.000$ ).

**Table 2.** Patients and controls' cardiac parameters

	<b>Patients (n=61)</b>	<b>Control (n=27)</b>	<b>p</b>
Age	46.57 $\pm$ 9.65	43.55 $\pm$ 8.06	0.315
ADM (pg/mL)	96.295 $\pm$ 19.424	4.191 $\pm$ 0.543	<0.0001
GDF15 (pg/mL)	1247.049 $\pm$ 854.335	41.089 $\pm$ 14.884	<0.0001
ANP (pg/mL)	334.016 $\pm$ 40.874	58.200 $\pm$ 19.592	<0.0001

Table 3 reveals that the rheumatic parameters indicate that the CRP levels exhibited a significant reduction in the control group (0.756 mg/l) compared to the G1 group (45.600 mg/l), third-month sDMARD therapy group (7.045 mg/l), and the G3 therapy G3 group (bDMARD) (6.479 mg/l). No significant differences were observed between the treatment groups. The control group exhibited significantly lower SAA4 levels ( $2.21 \pm 0.647$  ng/mL) compared to the other three groups. The G1 (43.28 ng / mL) G2 (50.4 ng/mL), and G3 (53.7 ng/mL) groups did not exhibit significant differences. The control group exhibited AGT levels of 3.57  $\mu$ g/mL, which were markedly lower compared to the G1 group at 34.71  $\mu$ g/mL, the G2 group at 43.5  $\mu$ g/mL, and the G3 group at 41.23  $\mu$ g/mL.

**Table 3.** Comparison of rheumatic parameters in patients before and after treatment compared to a control group\*

	<b>Control (n=27)</b>	<b>Pretreatment G1 (n=10)</b>	<b>Third month sDMARDs therapy G2 (n=22)</b>	<b>bDMARDs Therapy G3 (n=29)</b>	<b>p</b>
Age	43.55 $\pm$ 8.06 <sup>A</sup>	47.90 $\pm$ 11.87 <sup>A</sup>	47.09 $\pm$ 10.84 <sup>A</sup>	45.72 $\pm$ 8.04 <sup>A</sup>	0.4
SAA4 (ng/mL)	2.21 $\pm$ 0.647 <sup>A</sup>	43.28 $\pm$ 13.46 <sup>B</sup>	50.4 $\pm$ 32.7 <sup>B</sup>	53.7 $\pm$ 30.6 <sup>B</sup>	<0.0001
AGT ( $\mu$ g/mL)	3.573 $\pm$ 1.41 <sup>A</sup>	38.71 $\pm$ 16.41 <sup>B</sup>	43.5 $\pm$ 20.82 <sup>B</sup>	41.23 $\pm$ 16.74 <sup>B</sup>	<0.0001
CRP (mg/L)	0.756 $\pm$ 0.109 <sup>A</sup>	45.600 $\pm$ 28.733 <sup>B</sup>	7.045 $\pm$ 4.673 <sup>A</sup>	6.479 $\pm$ 4.041 <sup>A</sup>	<0.0001

\* Capital letters A, B, and C were used to indicate the level of significance following Dunn's multiple comparison test; similar letters indicate no significant difference, whereas different letters indicate significant differences

Table 4 shows that the level of ADM was significantly lower in the control group (4.191 pg/mL) than in the G1 pretreatment G1 group (99.800 pg/mL), the G2 group (95.591 pg/mL), and the bDMARDs G3 group bDMARDs (95.621 pg/mL), as illustrated in Figure 3. Groups G1, G2 and G3 showed no significant differences. At the GDF15 levels in the control group (41.089 pg/mL) were much lower than in the other three groups. The G1 (2030.1 pg/mL) G2 (1964 pg/mL), and G3 (382.6 pg/mL) groups did not exhibit significant differences. Similarly, ANP levels were markedly reduced in the control group (57.5 pg/mL) compared to those in the other three groups. G1 (305.6 pg/mL), G2 (36.5 pg/mL) and G3 (323.8 pg/mL), with G1 showing a considerable difference from G2.

**Table 4.** Cardiac parameters in patients before and after treatment relative to the control group\*

	<b>Control (n=27)</b>	<b>Pretreatment G1 (n=10)</b>	<b>sDMARDs G2 (n=22)</b>	<b>bDMARDs G3 (n=29)</b>	<b>p</b>
Age	43.55±8.06 <sup>A</sup>	47.90±11.87 <sup>A</sup>	47.09±10.84 <sup>A</sup>	45.72±8.04 <sup>A</sup>	0.4
ADM (pg/mL)	4.19±0.86 <sup>A</sup>	100.9±22.48 <sup>B</sup>	95.6±20.2 <sup>B</sup>	92.6±25.6 <sup>B</sup>	<0.0001
GDF15 (pg/mL)	41.89±14.84 <sup>A</sup>	2030.1±261 <sup>B</sup>	1964±470.9 <sup>B</sup>	382.6±107 <sup>C</sup>	<0.0001
ANP (pg/mL)	57.5±18.7 <sup>A</sup>	305.6±29.14 <sup>B</sup>	360.5 ±40.77 <sup>C</sup>	323.8±33.4 <sup>B</sup>	<0.0001

\* Capital letters A, B, and C were used to indicate the level of significance following Dunn's multiple comparison test; similar letters indicate no significant difference, whereas different letters indicate significant differences

ADM had a substantial association with all other cardiac and rheumatic indicators, as shown by a Spearman correlation value over 0.6. GDF15 was significantly correlated with the cardiac parameters of ANP and CRP. Among rheumatic markers, ANP has been shown to correlate with SAA4. Rheumatic CRP, which did not show a connection. The relationship between SAA4 and AGT, as indicated by Spearman's correlation coefficient presented in Table 5.

**Table 5.** Correlation of all parameters

<b>Parameters</b>		<b>GDF15</b>	<b>ANP</b>	<b>CRP</b>	<b>SAA4</b>	<b>AGT</b>
<b>ADM</b>	r	0.660	0.653	0.675	0.612	0.629
	p	0.0001	0.0001	0.0001	0.0001	0.0001



<b>GDF15</b>	r	1.000	0.685	0.724	0.590	0.599
	p		0.0001	0.0001	0.0001	0.0001
<b>ANP</b>	r			0.561	0.600	0.590
	p			0.0001	0.0001	0.0001
<b>CRP</b>	r				0.589	0.591
	p				0.0001	0.0001
<b>SAA4</b>	r					0.755
	p					0.0001

## Discussion

CRP levels were significantly elevated in patients with RA (Table 1), with the patient group displaying markedly higher values than the control group. Previous research has demonstrated elevated CRP levels in patients with RA compared to healthy controls, since RA is a chronic inflammatory autoimmune disorder and CRP serve as an inflammation marker.<sup>28,29</sup>

Consistently elevated levels of SAA4 were identified in patients with RA compared to healthy controls, as indicated in Table 1 of the current investigation. This finding supports recent research.<sup>30,31</sup> which characterizes increased SAA4 levels to the systemic inflammatory nature of RA. SAA4, an acute phase protein, is classified as a pro-inflammatory cytokines, which stimulates the liver to produce SAA.<sup>32,33</sup> Previous studies have suggested that SAA4 may serve as a more effective marker of disease activity in RA than conventional inflammatory markers such as CRP and ESR, highlighting the importance of SAA4 in the context of RA pathogenesis.<sup>34</sup> Analysis of SAA4 levels between study groups revealed significant differences. The control group showed significantly lower SAA4 concentrations compared to G1, G2, and G3 (Table 3). Furthermore, no statistically significant changes were detected among the three experimental groups. In certain cases, patients with well-managed RA or remission may show lower SAA4 levels, indicating reduced inflammatory activity. Furthermore, specialized treatments, including biological agents that target specific inflammatory pathways, can effectively modulate SAA4 levels. Fragoulis observed that various therapies have varying effects on SAA4 levels in patients with RA, with certain treatments resulting in a significant drop, which differs from the results of the current study.<sup>35</sup>

This study revealed statistically significant differences in AGT values between the patient and control groups (Table 3). This finding aligns with previous studies that have consistently indicated higher AGT levels in patients compared to healthy controls.<sup>36</sup> Unlike SAA4, AGT levels in RA patients are associated with dysregulated function and activity of the renin-angiotensin-aldosterone system (RAAS) under pathological conditions. In patients with chronic inflammation, such as RA, increased activation of the RAAS system leads to elevated production of AGT in the liver and tissues, which subsequently increases

angiotensin II levels, which results in hypertension and vascular damage.<sup>37</sup> In RA, cytokine levels are elevated, which promotes the production of AGT.<sup>38</sup> The current study did not reveal significant differences across G1, G2, and G3. Low levels of AGT in RA are rare or nonexistent, but may be linked to liver dysfunction, effective inflammation control, or metabolic variables.<sup>39</sup>

In critically ill patients, elevated serum levels of ADM were observed in comparison to controls. Individuals exhibited significantly higher levels of ADM compared to healthy controls, as shown in Table (2), corroborating extensive research that identifies ADM as a potent biomarker closely linked to heart failure, especially in patients with RA.<sup>40,41</sup> Elevated levels of ADM in RA are correlated with chronic inflammation, hypoxia, and vascular dysfunction within synovial tissue.<sup>42</sup> Despite the anti-inflammatory and protective properties of ADM, its overproduction indicates the body's effort to mitigate the pathological processes associated with RA.<sup>43,44</sup> Elevated ADM levels can function as a biomarker for cardiac disease activity and severity; however, direct investigations of ADM levels in RA patients are limited. Its role as a biomarker in other conditions (eg, sepsis and cardiovascular disease) indicates that it could act as a prognostic marker in RA, especially in patients with severe disease or those who did not respond to treatment.<sup>45,46</sup> However, no significant differences in ADM levels were observed between G1, G2 and G3 (Table 4).

The current study demonstrated statistically significant elevations in RA GDF-15 levels in patients compared to healthy controls, as shown in Table (2). These findings correspond to those of a concurrent study that reported similar results.<sup>47</sup> GDF-15 may function as a biomarker for disease activity and could indicate an elevated risk of cardiovascular complications in patients.<sup>48,49</sup> Groups G1 and G2 did not exhibit significant differences, suggesting that these cohorts demonstrate comparable GDF-15 expression. In particular, G3 had significant differences compared to both G1 and G2 (Table 4), indicating that G3 had lower levels of GDF-15, possibly due to the effects of the biologic therapy. The study emphasized the association between GDF-15 and atherosclerosis, demonstrating a gradual elevation of these levels in patients with RA.<sup>50</sup> GDF-15 levels showed a favorable correlation with markers of disease activity. This indicates that GDF-15 can contribute to the pathophysiology of RA and may function as a biomarker for monitoring disease progression.<sup>51</sup>

The study results revealed statistically significant elevations in ANP levels compared to the control group, as shown in Table (2). These findings are consistent with previous studies that demonstrated a correlation between ANP levels and patients with chronic heart failure and RA.<sup>52,53</sup> The observed elevation of ANP in RA patients is probably due to the synergistic effects of chronic inflammation, fluid retention, and cardiovascular stress. ANP regulates fluid balance, vascular tone, and blood pressure, serving as a compensatory mechanism to protect the cardiovascular system from the adverse effects of chronic inflammation in RA.<sup>54</sup> G1, G2, and G3 exhibited equivalent levels of ANP, with no statistically significant differences identified between them. G2 exhibited significantly higher ANP levels compared to G1 and G3.

This discrepancy suggests a possible involvement of ANP in the etiology of the disease or as an indicator of the underlying pathological alterations related to RA. The results indicated a significant difference in ANP concentrations between patients with active RA and those in remission; specifically, patients with active RA demonstrated significantly elevated levels of ANP than their counterparts in remission.<sup>55,56</sup> ADM exhibited a strong correlation with many cardiac and rheumatic parameters, as shown in Table (5); however, GDF15 and ANP exhibited moderate correlations. CRP levels exhibited a modest correlation with SAA4 and AGT levels.

## **Conclusion**

This study identified notable variations in biomarker levels among RA patients, particularly those with elevated CRP, SAA4, AGT, ADM, GDF-15 and ANP, especially within the pretreatment, chemotherapy and biological treatment groups compared to the control group. SAA4 and GDF-15 are proposed as potential biomarkers of disease activity and progression, with biological treatments linked to a reduction in GDF-15 levels. ADM and ANP levels also exhibited an increase. The findings can help evaluate the severity of the disease, track treatment responses and elucidating the cardiovascular implications of rheumatoid arthritis.

## **Acknowledgements**

The authors would like to thank the staff of Al-Basrah Teaching Hospital and Al-Mawanah Teaching Hospital in the Health Department of Basrah for contributing to the success of this work, which is part of the requirement for obtaining a master's degree. The authors are grateful to the laboratory personnel at Al-Basrah Teaching Hospital and Al-Mawanah Teaching Hospital, affiliated with the Health Department of Basrah, for their outstanding assistance and steadfast commitment throughout the sample collection procedure.

## **Declarations**

### ***Funding***

The study received no external funding.

### ***Author contributions***

Conceptualization, A.A.A. and A.M.J.; Methodology, A.A.A.; Software, A.A.A.; Validation, A.A.A., A.M.J.; Formal Analysis, A.A.A.; Investigation, A.A.A.; Resources, A.A.A.; Data Curation, A.A.A.; Writing – Original Draft Preparation, A.A.A.; Writing – Review & Editing, A.A.A.; Visualization, A.A.A.; Supervision, A.M.J.; Project Administration, A.M.J.; Funding Acquisition, A.A.A.

### ***Conflicts of interest***

The authors confirm that there are no conflicts of interest to disclose.

### ***Data availability***

The data sets used and analyzed during the current study are available from the corresponding author upon reasonable request.

### ***Ethics approval***

This study proposal was authorized by the research committee (number 860/2023) on December 23, 2023, in accordance with the Declaration of Helsinki.

### **References**

1. Zielińska A, Tabarkiewicz J. Correlation between rheumatoid arthritis and periodontitis. *Eur J Clin Exp Med*. 2022;(4):451-458. doi: 10.15584/ejcem.2022.4.11
2. Rohit N, Thakur B, Jain A, Jain PK, Khare B, Jat YS. Comprehensive Review on Rheumatoid Arthritis. *Int J Med Sci Pharma Res*. 2022;8(3):39-45. doi: 10.22270/ijmspr.v8i3.58
3. Zhou J, Wang F, Qu Y, et al. Lesions of Bones and Joints Associated with Rheumatism. In: *Radiology of Infectious and Inflammatory Diseases-Volume 5: Musculoskeletal System*. Springer; 2022:285-332. doi: 10.1007/978-981-16-5003-1\_9
4. Świtała A, Wyszynska J, Czerwińska K, Dereń K, Podgórska-Bednarz J, Guzik A. Association between body mass and physical activity with quality of life in patients with rheumatoid arthritis. *Eur J Clin Exp Med*. 2017;(3):200-205. doi: 10.15584/ejcem.2017.3.3
5. Li XC, de Oliveira Leite AP, Chen X, et al. The intratubular and intracrine renin-angiotensin system in the proximal tubules of the kidney and its roles in angiotensin II-induced hypertension. In: *Selected Chapters from the Renin-Angiotensin System*. IntechOpen; 2019.
6. Ghafar MTA. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension. *Steroids*. 2020;163:108701. doi: 10.1016/j.steroids.2020.108701
7. Cantero-Navarro E, Fernandez-Fernandez B, Ramos AM, et al. Renin-angiotensin system and inflammation update. *Mol Cell Endocrinol*. 2021;529:111254. doi: 10.1016/j.mce.2021.111254
8. Méndez-García LA, Escobedo G, Minguer-Urbe AG, et al. Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations. *Front Cell Neurosci*. 2022;16:977039. doi: 10.3389/fncel.2022.977039
9. Abouelasrar Salama S, Gouwy M, Van Damme J, Struyf S. The turning away of serum amyloid A biological activities and receptor usage. *Immunology*. 2021;163(2):115-127. doi:

10.1111/imm.13295

10. Sunar I, Ataman Ş. Serum C-reactive protein/albumin ratio in rheumatoid arthritis and its relationship with disease activity, physical function, and quality of life. *Arch Rheumatol*. 2020;35(2):247. doi: 10.46497/ArchRheumatol.2020.7456
11. Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of cardiac natriuretic peptides in heart structure and function. *Int J Mol Sci*. 2022;23(22):14415. doi: 10.3390/ijms232214415
12. Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. *Front Cardiovasc Med*. 2022;9:933215. doi: 10.3389/fcvm.2022.933215
13. Polyakova EA, Mikhaylov EN, Sonin DL, Cheburkin Y V, Galagudza MM. Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. *J Geriatr Cardiol JGC*. 2021;18(1):47. doi: 10.11909/j.issn.1671-5411.2021.01.007
14. Rahbar Kouibaran F, Sabatino M, Barozzi C, Diemberger I. Atrial natriuretic peptides as a bridge between atrial fibrillation, heart failure, and amyloidosis of the atria. *Int J Mol Sci*. 2023;24(7):6470. doi: 10.3390/ijms24076470
15. Novikova D, Kirillova I, Markelova E, et al. P4434The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up. *Eur Heart J*. 2019;40(Supplement\_1):ehz745.0836. doi:10.1093/eurheartj/ehz745.0836
16. O'Neill RS, Emmanuel S, Williams D, Stoita A. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort. *World J Gastroenterol*. 2020;26(14):1660. doi: 10.3748/wjg.v26.i14.1660
17. Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. *Front Immunol*. 2020;11:951. doi: 10.3389/fimmu.2020.00951
18. Luo H. GDF15 in Doxorubicin Cardiotoxicity. 2022.
19. Brenière C, Méloux A, Pédard M, et al. Growth differentiation factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. *Front Neurol*. 2019;10:611. doi: 10.3389/fneur.2019.00611
20. Jewad AM, Shwayel AJ. Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major. *Lab Med*. 2024;lmae007. doi: 10.1093/labmed/lmae007
21. Fischer JP, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin—current perspective on a peptide hormone with significant therapeutic potential. *Peptides*. 2020;131:170347. doi: 10.1016/j.peptides.2020.170347
22. Litmanovich A, Moady G, Saad M, Blumberg Y, Ertracht O, Qvit N. Cardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. *Peptide and Peptidomimetic Therapeutics*.

- 2022;579-614. doi: 10.1016/B978-0-12-820141-1.00013-3
23. Kaufmann P, Ilina Y, Press M, Bergmann A. Sandwich immunoassay for adrenomedullin precursor and its practical application. *Sci Rep.* 2024;14(1):28091. doi: s41598-024-79542-5
  24. Chiorescu RM, Lazar RD, Buksa SB, Mocan M, Blendea D. Biomarkers of volume overload and edema in heart failure with reduced ejection fraction. *Front Cardiovasc Med.* 2022;9:910100. doi: 10.3389/fcvm.2022.910100
  25. Simonavičius J, Mikalauskas A, Čerlinskaitė K, et al. Biologically Active Adrenomedullin (bio-ADM) is of Potential Value in Identifying Congestion and Selecting Patients for Neurohormonal Blockade in Acute Dyspnea. *Am J Med.* 2022;135(7):e165-e181. doi: 10.1016/j.amjmed.2022.02.006
  26. Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. *Cells.* 2021;10(11):2857. doi: 10.3390/cells10112857
  27. Shapiro SC. Biomarkers in rheumatoid arthritis. *Cureus.* 2021;13(5):e15063. doi: 10.7759/cureus.15063
  28. Fathy HM, Rafat S, Abd-ElAzeem MI, Abdou LM, Abd Elbaset AS, Tantawy M. CRP-Albumin Ratio as A Disease Activity Marker in RA Patients, Its Correlation with Musculoskeletal Sonography. *Egypt J Hosp Med.* 2023;92(1):5496-5502. doi: 10.21608/ejhm.2023.305791
  29. Cooper J, Pastorello Y, Slevin M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. *Front Immunol.* 2023;14:1087571. doi: 10.3389/fimmu.2023.1087571
  30. Cuesta-López L, Escudero-Contreras A, Hanaee Y, et al. Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling. *Front Immunol.* 2024;15:1333995. doi: 10.3389/fimmu.2024.1333995
  31. Zhou J, Dai Y, Lin Y, Chen K. Association between serum amyloid A and rheumatoid arthritis: A systematic review and meta-analysis. *Seminars in Arthritis and Rheumatism.* 2022;52:151943. doi: 10.1016/j.semarthrit.2021.12.011
  32. Speelman T, Dale L, Louw A, Verhoog NJD. The association of acute phase proteins in stress and inflammation-induced T2D. *Cells.* 2022;11(14):2163. doi: 10.3390/cells11142163
  33. Jrad AIS, Trad M, Bzeih W, El Hasbani G, Uthman I. Role of pro-inflammatory interleukins in osteoarthritis: a narrative review. *Connect Tissue Res.* 2023;64(3):238-247. doi: 10.1080/03008207.2022.2157270
  34. Sorić Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. *Front Immunol.* 2021;11:631299. doi: 10.3389/fimmu.2020.631299
  35. Fragoulis GE, Soulaïdopoulos S, Sfrikakis PP, Dimitroulas TD, Kitas G. Effect of biologics on

- cardiovascular inflammation: mechanistic insights and risk reduction. *J Inflamm Res*. 2021;1915-1931. doi: 10.2147/JIR.S282691
36. Mostafa TM, Hegazy SK, Elshebini EM, Saif DS, Elabd AH. A comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity. *Indian J Med Res*. 2020;152(4):393-400. doi: 10.4103/ijmr.IJMR\_640\_19
  37. Lin K, Luo W, Yan J, et al. TLR2 regulates angiotensin II-induced vascular remodeling and EndMT through NF- $\kappa$ B signaling. *Aging (Albany NY)*. 2020;13(2):2553. doi: 10.18632/aging.202290
  38. Satou R, Franco M, Dugas CM, Katsurada A, Navar LG. Immunosuppression by mycophenolate mofetil mitigates intrarenal angiotensinogen augmentation in angiotensin II-dependent hypertension. *Int J Mol Sci*. 2022;23(14):7680. doi: 10.3390/ijms23147680
  39. Wang F, So KF, Xiao J, Wang H. Organ-organ communication: The liver's perspective. *Theranostics*. 2021;11(7):3317. [https://doi: 10.7150/thno.55795](https://doi.org/10.7150/thno.55795)
  40. Ferreira MB, Fonseca T, Costa R, et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. *Eur J Intern Med*. 2021;85:41-49. doi: 10.1016/j.ejim.2020.11.002
  41. Hu G, Peng X, He L, et al. Pro-adrenomedullin as an independent predictive biomarker for heart failure in atrial fibrillation and flutter. *ESC Hear Fail*. 2025. doi: 10.1002/ehf2.15196
  42. Wang X, Fan D, Cao X, et al. The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. *Antioxidants*. 2022;11(6):1153. doi: 10.3390/antiox11061153
  43. Mahmoodazdeh A, Shafiee SM, Sisakht M, Khoshdel Z, Takhshid MA. Adrenomedullin protects rat dorsal root ganglion neurons against doxorubicin-induced toxicity by ameliorating oxidative stress. *Iran J Basic Med Sci*. 2020;23(9):1197. doi: 10.22038/ijbms.2020.45134.10514
  44. Garduno A, Cusack R, Leone M, Einav S, Martin-Loeches I. Multi-omics endotypes in ICU sepsis-induced immunosuppression. *Microorganisms*. 2023;11(5):1119. doi: 10.3390/microorganisms11051119
  45. Ye L, Zuo Y, Chen F, et al. Adrenomedullin expression is associated with the severity and poor prognosis of interstitial lung disease in dermatomyositis patients. *Front Immunol*. 2022;13:885142. doi: 10.3389/fimmu.2022.885142
  46. Sacco MA, Gualtieri S, Cordasco F, et al. The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature. *J Clin Med*. 2024;13(16):4847. doi: 10.3390/jcm13164847
  47. Arnold N, Rehm M, Büchele G, et al. Growth differentiation factor-15 as a potent predictor of long-term mortality among subjects with osteoarthritis. *J Clin Med*. 2020;9(10):3107. doi: 10.3390/jcm9103107

48. di Candia AM, de Avila DX, Moreira GR, Villacorta H, Maisel AS. Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. *Am Hear J Plus Cardiol Res Pract.* 2021;9:100046. doi: 10.1016/j.ahjo.2021.100046
49. Abdulridha GAO, Hussein MA, Majeed SR. High Growth Differentiation Factor-15 (GDF-15) in Rheumatoid Arthritis Patients Potential Risk for Cardiovascular Disease. *J Angiother.* 2024;8(3):1-8. doi: 10.25163/angiotherapy.839595
50. Hofstedt O, Wahlin B, Södergren A. Associations between serological biomarkers and subclinical atherosclerosis in patients with rheumatoid arthritis after 11 years of follow-up. *Clin Exp Rheumatol.* 2024;42(5):967-973. doi:10.55563/clinexprheumatol/70qiy8
51. Tanrikulu O, Sarıyıldız MA, Batmaz İ, et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. *Acta Reumatol Port.* 2017;(1).doi:ncbi.nlm.nih.gov/27679935/
52. Gangnus T, Burckhardt BB. Potential and limitations of atrial natriuretic peptide as biomarker in pediatric heart failure-a comparative review. *Front Pediatr.* 2019;6:420. doi: 10.3389/fped.2018.00420
53. Ankudinov AS. Association of pentraxin-3 and atrial natriuretic peptide in patients with chronic heart failure and rheumatoid arthritis. *Atherosclerosis.* 2021;331:e268. doi: 10.1016/j.atherosclerosis.2021.06.822
54. da Silva GJJ, Altara R, Booz GW, Cataliotti A. Atrial natriuretic peptide31-67: a novel therapeutic factor for cardiovascular diseases. *Front Physiol.* 2021;12:691407. doi: 10.3389/fphys.2021.691407
55. Raud B, Gay C, Guiguet-Auclair C, et al. Level of obesity is directly associated with the clinical and functional consequences of knee osteoarthritis. *Sci Rep.* 2020;10(1):3601.doi: s41598-020-60587-1
56. Dubiel-Braszczok B, Nowak K, Owczarek A, Engelmann M, Gumkowska-Sroka O, Kotyla PJ. Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab. *Curr Pharm Des.* 2022;28(24):2029-2037. doi: 10.2174/1381612828666220527141532